Repeatable battery for assessment of neuropsychological status in early Parkinson's disease

Movement Disorders

Volumn 24, Issue 10, 2009, Pages 1453-1460

  Yang, Chengwu ^a   Garrett Mayer, Elizabeth ^a   Schneider, Jay S ^b   Gollomp, Stephen M ^b,c   Tilley, Barbara C ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

Confirmatory factor analysis; Exploratory factor analysis; Parkinson's disease; Psychometric properties; RBANS

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; CONFIRMATORY FACTOR ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; EXPLORATORY FACTOR ANALYSIS; FACTORIAL ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RELIABILITY; REPEATABLE BATTERY FOR ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 69849089735     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22552     Document Type: Article

References (24)

1. McKay C, Casey JE, Wertheimer J, Fichtenberg NL. Reliability and validity of the RBANS in a traumatic brain injured sample. Arch Clin Neuropsychol 2007;22:91-98.
2. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-319.
3. Wilde MC. The validity of the repeatable battery of neuropsychological status in acute stroke. Clin Neuropsychol 2006;20:702-715.
4. Larson EB, Kirschner K, Bode R, Heinemann A, Goodman R. Construct and predictive validity of the Repeatable Battery for the Assessment of Neuropsychological Status in the Evaluation of Stroke Patients. J Clin Exp Neuropsychol 2005;27:16-32.
5. Beatty WW, Ryder KA, Gontkovsky ST, Scott JG, McSwan KL, Bharucha KJ. Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Arch Clin Neuropsychol 2003;18:509-520.
6. Dittmann S, Seemüller F, Schwarz MJ, et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord 2007;9:63-70.
7. Aupperle RL, Beatty WW, Shelton Fde N, Gontkovsky ST. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult Scler 2002;5:382-389.
8. Beatty WW. RBANS analysis of verbal memory in multiple sclerosis. Arch Clin Neuropsychol 2004;19:825-834.
9. Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res 2004;70:175-186.
10. Duff K, Langbehn DR, Schoenberg MR, et al. Examining the Repeatable Battery for the Assessment of Neuropsychological Status: factor analytic studies in an elderly sample. Am J Geriatr Psychiatry 2006;14:976-979.
11. Garcia C, Leahy B, Corradi K, Forchetti C. Component structure of the Repeatable Battery for the Assessment of Neuropsychological Status in dementia. Arch Clin Neuropsychol 2008;23:63-72.
12. Carlozzi NE, Horner MD, Yang C, Tilley BC. Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status. Appl Neuropsychol 2008;15:1-6.
13. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): manual. San Antonio, TX: The Psychological Corporation; 1998.
14. NIH, PA-06-194. Research on the cognitive sequelae of Parkinson's Disease (R03). Available at: http://grants.nih.gov/grants/guide/pa-files/ PA-06-194.html#SectionIII. Accessed September 9, 2008.
15. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
16. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20-28.
17. Kline RB. Principles and practice of structural equation modeling, 2nd ed. New York: The Guilford Press; 2005. 59 p.
18. Brown, TA. Confirmatory factor analysis for applied research. New York: The Guilford Press; 2006. 87 p.
19. Zumbo BD. Validity: foundational issues and statistical methodology. In: Rao CR, Sinharay S, editors. Handbook of statistics, Vol.26: psychometrics. Amsterdam, Netherlands: North-Holland; 2007. p 45-79.
20. Hatcher L. A step-by-step approach to using SAS system for factor analysis and structure equation modeling. Cary, NC: SAS Institute Inc; 1994. 84 p.
21. Muthen LK, Muthen BO. Mplus Short courses: traditional latent variable modeling using Mplus. Los Angeles, CA: Muthen & Muthen; 2003. 16 p.
22. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
23. Skrondal A, Rabe-Hesketh S. Generalized latent variable modeling: multilevel, longitudinal, and structural equation models. Boca Raton, FL: Chapman & Hall/CRC; 2004. 35 p.
24. Cook DA, Beckman TJ. Current concepts in validity and reliability for psychometric instruments: theory and application. Am J Med 2006;119:166.e7-e16.